Oramed Pharmaceuticals (ORMP) Cash from Financing Activities (2010 - 2026)

Oramed Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$10.4 million for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to -$10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.9 million (changed N/A YoY) and the FY2025 annual result came in at -$4.7 million, up 90.89% from the prior year.
• Cash from Financing Activities was -$10.4 million for Q1 2026 at Oramed Pharmaceuticals, down from -$4.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $74.5 million in Q3 2023 and bottomed at -$30.6 million in Q2 2024.
• A 5-year average of -$286642.9 and a median of -$778000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 1628.45% — and 2024, when it slumped 881.89%.
• Oramed Pharmaceuticals' Cash from Financing Activities stood at $4.2 million in 2022, then sank by 698.8% to -$25.0 million in 2023, then jumped by 95.22% to -$1.2 million in 2024, then sank by 235.48% to -$4.0 million in 2025, then plunged by 158.52% to -$10.4 million in 2026.
• Business Quant data shows ORMP's Cash from Financing Activities at -$10.4 million in Q1 2026, -$4.0 million in Q4 2025, and -$361000.0 in Q3 2025.